[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351971-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-351971-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","subtype-specific-enhancer-rnas-define-transcriptional-regulators-and-prognosis-in-breast-cancers-research","Subtype-specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers - Research","","Enhancer RNAs (eRNAs) mark lineage-specific enhancer activity and can forecast treatment response and survival in breast cancer. Using machine learning on RNA-sequencing data from 975 patients and ~300,000 eRNA loci, the study identifies breast-cancer eRNAs specific to molecular subtypes and survival. ProxCReAm links subtype-specific eRNAs with co-expressed mRNAs and highlights subtype-characteristic pathways. Motif and cistrome analyses implicate nuclear receptors and FOX factors. Luminal eRNAs associate with better outcomes, whereas Her2 eRNAs associate with worse outcomes.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/subtype-specific-enhancer-rnas-define-transcriptional-regulators-and-prognosis-in-breast-cancers-research/351971/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/subtype-specific-enhancer-rnas-define-transcriptional-regulators-and-prognosis-in-breast-cancers-research/351971.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What are enhancer RNAs (eRNAs) and why are they important in breast cancer?","Question",{"text":63,"@type":64},"eRNAs are noncoding RNAs transcribed from DNA enhancers. Their expression reflects transcription factor activity and links to treatment response and patient survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers identify breast-cancer subtype-specific and prognostic eRNAs?",{"text":68,"@type":64},"They analyzed about 300,000 eRNA loci from RNA-sequencing datasets covering 975 breast cancer patients. Machine learning was used to categorize eRNAs by molecular subtype and survival relevance.",{"name":70,"@type":61,"acceptedAnswer":71},"What is ProxCReAm, and what did it reveal?",{"text":72,"@type":64},"ProxCReAm associates subtype-specific eRNAs with subtype-relevant proximal co-expressed mRNAs. It showed enrichment in pathways characteristic of each molecular subtype.",{"name":74,"@type":61,"acceptedAnswer":75},"How do eRNAs relate to prognosis across luminal and Her2 subtypes?",{"text":76,"@type":64},"Luminal eRNAs were associated with better patient outcomes, whereas Her2 eRNAs were associated with worse outcomes, indicating subtype-dependent prognostic value.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},351971,1790458043,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Subtype-speciﬁc enhancer RNAs deﬁne transcriptional regulators and prognosis in breast cancers  \nAamena Y. Patel 1,2, Peyman Zarrineh3, Nathnael T. Tuffa 1 , Jigar H. Sheth 1, Sumitra Mohan 1, Mudassar Iqbal4 and Sankari Nagarajan 1   \n1 Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK  \n2 Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK  \n3 Bioinformatics Core Facility, Faculty of Biology, Medicine and Health, The University of Manchester, UK  \n4 Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK  \nKeywords  \nbreast cancer; enhancer RNA; information gain; machine learning; random forest  \nCorrespondence  \nS. Nagarajan, Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PL, UK  \nE-mail: [sankari.nagarajan@manchester.ac.uk](sankari.nagarajan@manchester.ac.uk)  \n[Aamena Y. Patel](Aamena Y. Patel), [Peyman Zarrineh and](Peyman Zarrineh and)[ ](Peyman Zarrineh and)[Nathnael T. Tuffa are co-](Nathnael T. Tuffa are co-)ﬁ[rst authors](rst authors).  \n(Received 6 June 2025, revised 8 November 2025, accepted 21 January 2026, available online 2 March 2026)  \ndoi:10 . 1002/1878-0261 .70214  \nGene expression is tightly controlled by DNA elements called enhancers by associating with lineage-speciﬁc transcription factors. These enhancers transcribe noncoding RNAs (called enhancer RNAs or eRNAs) . eRNA expression is an early indicator of transcription factor activity and is associated with treatment response and survival in cancer patients. By analysing~ 300 000 eRNA loci proﬁled using RNA-sequencing data sets from 975 breast cancer patients using machine learning approaches, we categorised eRNAs speciﬁc to breast cancer molecular subtypes and survival. We associated these eRNAs with subtype-speciﬁc mRNAs to deﬁne proximal co-expressed regulatory eRNAs (ProxCReAm), which are enriched in pathways characteristic of their respective subtypes. Interestingly, cistrome and transcription factor motif analyses on these eRNAs highlighted involvement of diverse nuclear receptors (GR/AHR for luminal and GR/RAR for basal) and FOX factors in luminal regions. Moreover, luminal eRNAs were associated with better outcomes and Her2 eRNAs with worse outcomes in patients. Overall, we demonstrate that machine learning approaches performed on RNA-seq data sets can classify functionally relevant subtype-speciﬁc and prognostic eRNAs, which can identify critical gene pathways and transcription factor networks in breast cancer.  \nAbbreviations  \nAHR, aryl hydrocarbon receptor; AME, Analysis of Motif Enrichment; ATAC, assay for transposase-accessible chromatin; CAGE, Cap Analysis of Gene Expression; CGP, chemical and genetic perturbations; CHD8, Chromodomain-helicase DNA binding protein; ChIP, chromatin immunoprecipitation; CPM, counts per million; CREBBP, Cyclic AMP response element-binding protein; ER, oestrogen receptor; eRNAs, enhancer RNAs; FN, false negative; FP, false positive; GR, glucocorticoid receptor; GRO-seq, Global Run-on sequencing; Her2, human epidermal growth factor receptor-2; HIF1A, Hypoxia-inducible factor 1 alpha; InfoGain, information gain; KAS-seq, kethoxal-assisted single-stranded DNA sequencing; Logmc, log mean centring; MAD, median-absolute-deviation; PC, principal component; PCA, principal component analysis; PEGS, Peak set Enrichment in Gene Sets; PR, progesterone receptor; ProxCReAms, Proximally Co-expressed Regulatory eRNAs, which are Associated with mRNAs; RNAPII, RNA polymerase II; Rpkm, reads per kilobase per million mapped reads; SMARCA4, SWI/SNF Related BAF Chromatin Remodelling Complex Subunit ATPase-4; SPI","cbCaivO1IONJsCJ9","https://ap.wps.com/l/cbCaivO1IONJsCJ9","pdf",3497962,22,"English","# Introduction\n## Breast cancer heterogeneity and molecular subtypes\n## Role of enhancer RNAs (eRNAs) in transcription regulation\n# Methods and analysis framework\n## RNA-seq eRNA locus profiling and machine learning\n## ProxCReAm: linking eRNAs to subtype mRNAs\n# Findings\n## Subtype-specific co-expressed regulatory eRNAs\n## Transcription factor motifs and cistrome insights\n## Prognostic associations across subtypes","[{\"question\":\"What are enhancer RNAs (eRNAs) and why are they important in breast cancer?\",\"answer\":\"eRNAs are noncoding RNAs transcribed from DNA enhancers. Their expression reflects transcription factor activity and links to treatment response and patient survival.\"},{\"question\":\"How did the researchers identify breast-cancer subtype-specific and prognostic eRNAs?\",\"answer\":\"They analyzed about 300,000 eRNA loci from RNA-sequencing datasets covering 975 breast cancer patients. Machine learning was used to categorize eRNAs by molecular subtype and survival relevance.\"},{\"question\":\"What is ProxCReAm, and what did it reveal?\",\"answer\":\"ProxCReAm associates subtype-specific eRNAs with subtype-relevant proximal co-expressed mRNAs. It showed enrichment in pathways characteristic of each molecular subtype.\"},{\"question\":\"How do eRNAs relate to prognosis across luminal and Her2 subtypes?\",\"answer\":\"Luminal eRNAs were associated with better patient outcomes, whereas Her2 eRNAs were associated with worse outcomes, indicating subtype-dependent prognostic value.\"}]","Subtype-specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers - Research | PDF",1790096638,55,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6877aae116994ff75c4b03ab2441bda.webp",983,1291,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4eb5bc6b96f94dfc16038c6688dfffba.webp",982,1290,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecc266e7f1997133c63afdd857dea10e.webp",981,1289,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eaa917f52391ff81c5671fb266aa80a8.webp",980,1287]